Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.…
Adicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus Data
Adicet Bio (NASDAQ: ACET) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 102 employees.
The shares were at 2.140 USD on 20 November 2026, down 82.2% over 52 weeks. Its 52-week range is 2.120 USD to 12.96 USD, and it trades at the bottom of that range.
Its market capitalisation is 20.03M USD.
Adicet Bio reports return on equity of -73.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 88.84M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.